Mayne Pharma Secures Extended Exclusivity for Imvexxy Through 2032 in Settlement with Teva Pharmaceuticals
In a strategic legal maneuver, Mayne Pharma has reached a settlement with Teva Pharmaceuticals USA Inc. over the market entry of a generic version of Imvexxy, an oestradiol vaginal insert. This agreement, announced recently, stipulates that Teva will delay launching its generic alternative until 2032, extending Mayne Pharma’s market exclusivity for several more years. This…